Biopartnering Seminar Series - Cosentyx Seminar - By: Team Poseidon Consulting Group
Abstract: Plaque psoriasis (PsO) is a chronic auto-inflammatory condition that exhibits as itchy, red, scaly patches on the skin and is estimated to impact approximately 2% of the population. Although a majority of cases are mild, the moderate-to-severe cases can be debilitating to many and yield a variety of comorbidities due to the systemic inflammation associated with the disease. Common comorbidities include psoriatic arthritis, ankylosing spondylitis, obesity, and cardiovascular disease. Fortunately, there exists a monoclonal anti-IL-17A antibody therapy, secukinumab (Cosentyx) to treat psoriasis which has demonstrated efficacy, safety, and durability. Notably, there is promising evidence that Cosentyx demonstrates considerable efficacy in patients with comorbidities. However, Cosentyx is in a crowded field of biologics with persistent market entrants hoping to treat PsO through targeting interleukin inhibitors (IL-12/23 and IL-17) or TNFα. Accordingly, to maintain Novartis’ market share, there is a need to improve upon the positioning of Cosentyx. Poseidon Consulting proposes that Novartis differentiate themselves from competitors by leveraging a cross-functional, two-pronged approach involving medical and commercial efforts. The medical team will make use of advisory boards to generate key opinion leader insights on new clinical data involving Cosentyx and comorbidities, as well as what this means for the drug. Subsequently, continuing medical education learning programs will be developed to increase the understanding of physicians on the management of PsO patients with comorbidities. From a commercial perspective, strategies include crafting core messages which can be promoted by the sales team, specifically targeting emerging rheumatologists and dermatologists in the field.
(Access Passcode: %447MQh69U)